Special Seminar: Gene Therapy Targeting Vascular Function in Cardiovascular Disease: Are We There Yet?
Steven Fisher, M.D.
Professor
Department of Cardiology and Physiology
University of Maryland - Baltimore
Staff Physician
Baltimore VA Medical Center
Special Seminar: Gene Therapy Targeting Vascular Function in Cardiovascular Disease: Are We There Yet?
Date: May 20, 2022
Time: 11:00 a.m. - 12:00 p.m.
About this Seminar
This past decade has witnessed a renaissance in gene therapies for a broad array of human diseases. Dr. Fisher's talk will focus on mRNA splice variants as targets for gene therapies that by shifting the expression of naturally occurring protein isoforms may have therapeutic benefit. The specific focus is the smooth muscle myosin phosphatase (MP) enzyme, the end effector of vasodilation and key end target of signaling pathways regulating vessel tone and thus blood flow and blood pressure. Our data supports a model in which a splice variant of the MP regulatory subunit Mypt1 sets vascular sensitivity to NO , ANP, and ROS vasodilator signaling. After reviewing this data, Dr. Fisher will present his recent experiments testing the alternative gene therapy approaches of Crispr/Cas9 gene editing and splice-blocking anti-sense oligonucleotides targeting Mypt1 E24. These are potential novel therapies for hypertension and its sequelae HFpEF, the #1 preventable cause of early mortality world-wide.
You May Also Be Interested In...
-
Home Item
Biobehavioral Susceptibility for Obesity: Behavioral, Genetic and Neuroimaging Studies of Appetite , homeSept. 6, 2024, 11:00 a.m. | Susan Carnell, Ph.D., Associate Professor, Division of Child and Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine | Co-Sponsored by the Center for Health Behaviors Research and the Addiction Recovery Research Center, Fralin Biomedical Research Institute
-
Home Item
Conducting the Neuro-Symphony in the Brain — Space, Time, and Calcium , homeSept. 12, 2024, 5:30 p.m. (Reception at 5 p.m.) | Michael Friedlander, Ph.D., Executive Director, Fralin Biomedical Research Institute Vice President for Health Sciences and Technology, Virginia Tech Senior Dean for Research, Virginia Tech Carilion School of Medicine | Maury Strauss Distinguished Public Lecture
-
Home Item
Development of Genome Editor Therapies for Angelman Syndrome , homeSept. 13, 2024, 11:00 a.m. | Mark J. Zylka, Ph.D., W.R. Kenan, Jr. Distinguished Professor, University of North Carolina at Chapel Hill; Director, UNC Neuroscience Center | Co-Sponsored by the Center for Neurobiology Research, Fralin Biomedical Research Institute
-
Home Item
Understanding the Limits of Exercise Responsiveness in Older Adults , homeSept. 20, 2024, 11:00 a.m. | Ian R. Lanza, Ph.D., Professor of Medicine, Mayo Clinic College of Medicine and Science | Co-Sponsored by the Center for Exercise Medicine Research, Fralin Biomedical Research Institute
-
Home Item
From Variant Functionality to Resistance in Cancer , homeSept. 27, 2024, 11:00 a.m. | Tiki Hayes, Ph.D., Assistant Professor, Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Center – D.C.
-
Home Item
Disrupting Health Care Using Deep Data and Remote Monitoring , homeOct. 4, 2024, 11:00 a.m. | Michael Snyder, Ph.D., Professor, Genetics, Director, Center for Genomics and Personalized Medicine, Stanford Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Exercise Medicine Research